We’re excited to welcome Umlaut.bio to our portfolio. Umlaut.bio, a spin-off from EMBL in Heidelberg, is pioneering the development of small molecules inhibiting tRNA modifications for cancer and autoimmune therapies. The company has been funded by HTGF and LBBW Venture Capital, and also supported by Ono Pharmaceutical and Eli Lilly through the Mission BioCapital Platinum Program and AbbVie through the Golden Ticket. Our funding brings the pre-seed financing round to EUR 3 Million.
Umlaut.bio develops first-in-biology small molecules that inhibit enzymes involved in tRNA modifications, with the goal of solving shortcomings of current cancer and autoimmune treatments, such as therapy resistance and side effects. Their proprietary platform enables high-throughput screening and mass spectrometry-based validation of the inhibition of such enzymes and builds upon the seminal work conducted at EMBL by Dr Bastian Linder, now CSO at Umlaut.bio.
Led by Karsten Fischer (CEO), Bastian Linder (CSO) and Simon Breitler (CDO), Umlaut.bio has recently strengthened their Scientific Advisory Board with Prof. Dr. Oliver Distler, from the University of Zürich and a Key Opinion Leader in the field of Systemic Sclerosis program, and Prof. Dr. Tsutomu Suzuki, from the University of Tokyo and an expert in RNA biochemistry and tRNA modifications.
”With BaseLaunch, Umlaut was able to add significant expertise, as well as a top-tier network within the pharmaceutical industry. This will catalyze its preclinical development of therapeutic molecules based on this novel fundamental biological principle.
Karsten Fischer, Ph.D.Chief Executive Officer Umlaut.bio
Congratulations to the entire Umlaut.bio team on this exciting milestone!
